Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients.

About our SPEAR T-cells

Our TCR T-cell therapies have advantages over other immune therapies and cancer therapies.

Our SPEAR T-cell video below provides more information.

Our TCR T-cell therapies are capable of recognizing peptide fragments from both proteins present inside the cell and expressed on the outside of the cell. We can therefore target a large number of proteins.

More targets, inside the cancer cell and out, means more options for targeting these cancers.

Our T-cell therapies are all subjected to a meticulous pre-screening package which aims to minimize any chance that our T-cell therapies might bind to peptides other than the intended target cancer peptide.

Better specificity, we believe, improves the safety profile of our T-cell therapies.

Our T-cell therapies have general applicability to a wide range of cancer types, many of which currently have low patient survival rates. Read below to find out more information about each of our 3 products and the cancer types that they are targeting.

  • MAGE-A10Urothelial (bladder), Melanoma, Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
  • AFPHepatocellular (liver) cancer
  • MAGE-A4Urothelial (bladder), Melanoma, Ovarian, Non-Small Cell Lung Cancer (NSCLC), Esophageal, Gastric, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma (MRCLS), Head and Neck

We enhance the body's natural systems by affinity engineering naturally occurring T-cell receptors (TCRs) to recognize and bind to specific cancer peptides.

In addition to our clinical pipeline, we have a large pipeline of identified and validated targets against which we can direct new T-cell therapies.

We believe that our SPEAR T-cell therapies may one day be capable of treating patients who have limited, if any, treatments available.